Probing the isoprenylcysteine carboxyl methyltransferase (Icmt) binding pocket: sulfonamide modified farnesyl cysteine (SMFC) analogs as Icmt inhibitors

  • Bioorg Med Chem Lett. 2011 May 1;21(9):2616-20. doi: 10.1016/j.bmcl.2011.01.078.
Jaimeen D Majmudar  1 ,  Kalub Hahne ,  Christine A Hrycyna ,  Richard A Gibbs
Affiliations
  • 1. Department of Medicinal Chemistry and Molecular Pharmacology and the Purdue University Center for Cancer Research, Purdue University, West Lafayette, IN 47907, USA.
PMID: 21334890 DOI: 10.1016/j.bmcl.2011.01.078
Abstract

Human isoprenylcysteine carboxyl methyltransferase (hIcmt) is a promising Anticancer target as it is important for the post-translational modification of oncogenic Ras proteins. We herein report the synthesis and biochemical activity of 41 farnesyl-cysteine based analogs versus hIcmt. We have demonstrated that the amide linkage of a hIcmt substrate can be replaced by a sulfonamide bond to achieve hIcmt inhibition. The most potent sulfonamide-modified farnesyl cysteine analog was 6ag with an IC(50) of 8.8±0.5 μM for hIcmt.

Products